Publications by Andrea Pfeifer

Targeting the TDP-43 low complexity domain blocks spreading of pathology in a mouse model of ALS/FTD

Andrea Pfeifer, Tariq Afroz, Monisha Ratnam

Abnormal cytoplasmic localization and accumulation of pathological transactive response DNA binding protein of 43 kDa (TDP-43) underlies several devastating diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP ...

BMC2024

Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework

Andrea Pfeifer, Tariq Afroz, Florence Gauye, Monisha Ratnam

Optimal pharmacokinetic (PK) properties of therapeutic monoclonal antibodies (mAbs) are essential to achieve the desired pharmacological benefits in patients. To accomplish this, we followed an approach comprising structure-based mAb charge engineering in ...

TAYLOR & FRANCIS INC2023

Structure-activity relationship around PI-2620 highlights the importance of the nitrogen atom position in the tricyclic core

Andrea Pfeifer

Tau aggregates represent a critical pathology in Alzheimer's disease (AD) and other forms of dementia. The extent of Tau neurofibrillary tangles across defined brain regions corresponds well to the observed level of cognitive decline in AD. Compound 1 (PI- ...

PERGAMON-ELSEVIER SCIENCE LTD2021

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease

Andrea Pfeifer

Tau has become an attractive alternative target for passive immunotherapy efforts for Alzheimer's disease (AD). The anatomical distribution and extent of tau pathology correlate with disease course and severity better than other disease markers to date. We ...

AMER ASSOC ADVANCEMENT SCIENCE2021

Discovery of 2-(4-(2-fluoroethoxy)piperidin-1-yl)-9-methyl-9H-pyrrolo[2,3-b:4,5-c']dipyridine ([18F]PI-2014) as PET tracer for the detection of pathological aggregated tau in Alzheimer's disease and other tauopathies

Andrea Pfeifer

The compound screening was initiated with a direct staining assay to identify compounds binding to Tau aggregates and not Abeta plaques using human brain sections derived from late stage Alzheimer's disease donors. The binding of Tau aggregate selective co ...

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER2020

A Short Synthesis of the 2-Bromo-N,9-dimethyl-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-6-amine Building Block

Andrea Pfeifer, Andreas Muhs

A concise synthesis of pharmaceutically useful (R)-tert-butyl N-(2-bromo-9-methyl-6,7,8,9-tetrahydro-5H-pyrido [2,3-b ] indol-6-yl) -N-methylcarbamate building block 11 is described. The racemic intermediate 17 was prepared in a single step from 2-bromo-6- ...

AMER CHEMICAL SOC2019

Calpain-mediated tau fragmentation is altered in Alzheimer's disease progression

Andrea Pfeifer, Andreas Muhs

The aggregation of intracellular tau protein is a major hallmark of Alzheimer's disease (AD). The extent and the stereotypical spread of tau pathology in the AD brain are correlated with cognitive decline during disease progression. Here we present an in-d ...

Nature Research2018

Synthesis and structure-activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of beta-amyloid-42 aggregation

Andrea Pfeifer, Andreas Muhs, Paolo Paganetti

It is assumed that amyloid-beta aggregation is a crucial event in the pathogenesis of Alzheimer's disease. Novel 2,6-disubstituted pyridine derivatives were designed to interact with the beta-sheet conformation of A beta via donor-acceptor-donor hydrogen b ...

Pergamon-Elsevier Science Ltd2016

Structure of Crenezumab Complex with A beta Shows Loss of beta-Hairpin

Andrea Pfeifer, Andreas Muhs, Bing Li

Accumulation of amyloid-beta (A beta) peptides and amyloid plaque deposition in brain is postulated as a cause of Alzheimer's disease (AD). The precise pathological species of A beta remains elusive although evidence suggests soluble oligomers may be prima ...

Nature Research2016

Cognitive Enhancers (Nootropics). Part 1: Drugs interacting with Receptors. Update 2014

Andrea Pfeifer, Andreas Muhs

Scientists working in the fields of Alzheimer's disease and, in particular, cognitive enhancers are very productive. The review "Cognitive enhancers (nootropics): drugs interacting with receptors" was accepted for publication in July 2012. Since then, new ...

Ios Press2014

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

Andrea Pfeifer, Andreas Muhs

Scientists working in the field of Alzheimer's disease and, in particular, cognitive enhancers, are very productive. The review "Drugs interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs" was accepted in October 2012. In the l ...

Ios Press2014

Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. Update 2014

Andrea Pfeifer, Andreas Muhs

Scientists working in the field of Alzheimer's disease and, in particular, cognitive enhancers are very productive. The review on Drugs interacting with Enzymes was accepted in August 2012. However, this field is very dynamic. New potential targets for the ...

Ios Press2014

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Andrea Pfeifer, Andreas Muhs

Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, app ...

Ios Press2013

TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice

Andrea Pfeifer, Marija Vukicevic, Valérie Gafner, Andreas Muhs, Anna Lucia Buccarello, Pedro Miguel Nunes Pereira de Almeida Reis

Immunoglobulin class switching from IgM to IgG in response to peptides is generally T cell-dependent and vaccination in T cell-deficient individuals is inefficient. We show that a vaccine consisting of a dense array of peptides on liposomes induced peptide ...

Amer Soc Hematology2013

Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes

Andrea Pfeifer, Andreas Muhs

Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, app ...

Ios Press2013

Dynamic Nuclear Polarization NMR Spectroscopy: Revealing Multiple Conformations in Lipid-Anchored Peptide Vaccines

Andrea Pfeifer, Andreas Muhs, Pedro Miguel Nunes Pereira de Almeida Reis

Wiley-VCH Verlag GmbH2013

Development of a Small D-Enantiomeric Alzheimer's Amyloid-beta Binding Peptide Ligand for Future In Vivo Imaging Applications

Andrea Pfeifer, Andreas Muhs

Alzheimer's disease (AD) is a devastating disease affecting predominantly the aging population. One of the characteristic pathological hallmarks of AD are neuritic plaques, consisting of amyloid-beta peptide (A beta). While there has been some advancement ...

Public Library Science2012

Discovery and Structure Activity Relationship of Small Molecule Inhibitors of Toxic β-Amyloid-42 Fibril Formation

Andrea Pfeifer, Hilal Lashuel, Mohammad Asad Jan Qureshi, Andreas Muhs, Annalisa Ansaloni, Paolo Paganetti, Magdalena Zweckstetter

Increasing evidence implicates Aβ peptides self-assembly and fibril formation as crucial events in the pathogenesis of Alzheimer disease. Thus, inhibiting Aβ aggregation, among others, has emerged as a potential therapeutic intervention for this disorder. ...

Amer Soc Biochemistry Molecular Biology Inc2012

Fluorine-18 labeling of three novel D-peptides by conjugation with N-succinimidyl-4-[F-18]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography

Andrea Pfeifer, Andreas Muhs

Introduction: beta-Amyloid (A beta) plaques and neurofibrillary tangles are the main characteristics of Alzheimer's disease (AD). Positron emission tomography (PET), a high-resolution, sensitive, and noninvasive imaging technique, has been widely utilized ...

2012